Navigation Links
Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
Date:4/22/2013

JERUSALEM, April 22, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that the Company's CEO Nadav Kidron has been invited to be a panelist for a breakouts session at the BIO International Convention in Chicago, Illinois, USA. The breakout session, titled "Can Israel Become the Next Biotech Start-Up Nation?" will take place on Tuesday, April 23rd, from 9:00-9:45am during the International Market Briefings Track.

Panel Description:

In the last 20 years, Israel has become a model for high tech entrepreneurship. A country of 8 million people, Israel is home to a vibrant academic biomedical research sector, a global pharmaceutical company and several public biotech companies. Yet, the success of Israel's biotech sector pales in comparison to its high-tech industry. What can be learned from the Israeli Hi-tech Innovation and Entrepreneurship model and how can it be applied to biotech? What can Israel learn from other success models in biotechnology such as Massachusetts or California? Which regional partnerships can best leverage Israel's potential? What is the optimal positioning for Israeli Biotech to encourage biopharma companies and investors to step up their involvement?

For more information on the panel please visit: http://mybio.zerista.com/event/member/64237

The BIO International Convention is hosted by the Biological Industry Organization (BIO) and is one of the largest and most widely attended annual conferences in the biotechnology sphere. For more information on BIO Chicago please visit: http://convention.bio.org/

About Oramed Pharmaceuticals  

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com.

The company's fact sheet, the content of which is not part of this press release, can be viewed here.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com 


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
2. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
3. Oramed Pharmaceuticals Announces Reverse Stock Split
4. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
5. Trigemina to Present at the 2013 BIO International Convention
6. Infinata’s BioPharm Insight to Offer Exclusive Preview of 2013 Key Reports at the BIO International Conference and Partnerships in Clinical Trials
7. Campbell Alliance to Release New Forward-Looking Industry Report on Deal-Making Trends at the 2013 BIO International Convention
8. 20 Swiss Biotech Firms and Organizations will Populate the Swiss Pavilion at BIO 2013 International Convention
9. Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
10. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
11. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 Oramed Pharmaceuticals Inc. ... www.oramed.com ), a clinical-stage pharmaceutical ... delivery systems, announced today that Dr. Miriam ... a presentation titled, "Oral Insulin for Diabetes Treatment: ... Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... , ... March 21, 2017 , ... ... biologics. To acquire information on the desired increase and/or decrease in antibody-dependent cellular ... for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, ...
Breaking Biology Technology:
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):